secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001140361-25-040539
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Q3 revenue $134.2M (+12% YoY); raises FY25 revenue guidance to $510M+, FY26 to $630M+
--------------------------------------------------------------------------------

- GAAP net income $36.4M (+1% YoY); adjusted EBITDA $58.7M (+29% YoY).
- Revenue guidance raised: FY25 to ≥$510M (from >$500M); FY26 to ≥$630M (from >$625M).
- Adj EBITDA guidance: FY25 reaffirmed at $235M; FY26 raised to >$355M (from >$340M).
- FDA lot release of first yield-enhanced batches; gross margin expansion expected from Q4 2025.
- Record ASCENIV demand; real-world data shows >50% infection reduction (2.1→0.9/year).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125040539/0001140361-25-040539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125040539/ef20058354_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-040539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer